• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

    118.28 +1.21 (+1.03%)
    Streaming Delayed Price Updated: 10:30 AM EDT, Jul 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mirum Pharmaceuticals, Inc. - common stock

    < Previous 1 2
    ...
    7 8 9 10 11 12 13 14 Next >
    News headline image
    Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    What 5 Analyst Ratings Have To Say About Mirum Pharmaceuticals ↗
    Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed ... 
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Participate in September Investor Conferences
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates ↗
    August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharma Out-Licenses Maralixibat Rights To GC Pharma in South Korea ↗
    Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and GC Pharma have entered into an exclusive licensing agreement to develop and commercialize Mirum's maralixibat... 
    Via Benzinga
    News headline image
    The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗
    Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
    Via Benzinga
    News headline image
    Stocks That Hit 52-Week Lows On Tuesday ↗
    During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the largest firm by market cap... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
    Via Benzinga
    News headline image
    Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal ↗
    CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million... 
    Via Talk Markets
    News headline image
    Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2
    ...
    7 8 9 10 11 12 13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.